Overview

Treatment of Patients With Major Depressive Disorder With MK0869 (0869-059)

Status:
Completed
Trial end date:
2004-03-24
Target enrollment:
Participant gender:
Summary
A clinical study to determine the efficacy and safety of MK0869 in the treatment of depression
Phase:
Phase 3
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.
Treatments:
Aprepitant
Fosaprepitant
Paroxetine